NTRKs are target of gene fusions, deletions/truncations and point mutations not only in hematological malignancies but also in various solid cancers that mostly lead to constitutive activity.107,108 Iacobucci et al19 found NTRK1 tyrosine kinase domain (H498R, G6117D, and H766R) mutations in tumor cells from 3 AEL patients carrying TP53 mutations. This evidence concerns the gene NTRK1 and neoplasm.